1. Home
  2. BOC vs ALT Comparison

BOC vs ALT Comparison

Compare BOC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOC
  • ALT
  • Stock Information
  • Founded
  • BOC 2009
  • ALT 1997
  • Country
  • BOC United States
  • ALT United States
  • Employees
  • BOC 452
  • ALT N/A
  • Industry
  • BOC
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • BOC
  • ALT Health Care
  • Exchange
  • BOC Nasdaq
  • ALT Nasdaq
  • Market Cap
  • BOC 443.8M
  • ALT 397.4M
  • IPO Year
  • BOC 2017
  • ALT N/A
  • Fundamental
  • Price
  • BOC $14.02
  • ALT $4.19
  • Analyst Decision
  • BOC Buy
  • ALT Strong Buy
  • Analyst Count
  • BOC 2
  • ALT 6
  • Target Price
  • BOC $20.00
  • ALT $18.20
  • AVG Volume (30 Days)
  • BOC 174.2K
  • ALT 11.7M
  • Earning Date
  • BOC 08-12-2025
  • ALT 08-07-2025
  • Dividend Yield
  • BOC N/A
  • ALT N/A
  • EPS Growth
  • BOC N/A
  • ALT N/A
  • EPS
  • BOC 0.03
  • ALT N/A
  • Revenue
  • BOC $110,452,664.00
  • ALT $20,000.00
  • Revenue This Year
  • BOC $9.19
  • ALT N/A
  • Revenue Next Year
  • BOC $6.50
  • ALT $1,557,547.90
  • P/E Ratio
  • BOC $519.55
  • ALT N/A
  • Revenue Growth
  • BOC 11.58
  • ALT N/A
  • 52 Week Low
  • BOC $12.83
  • ALT $2.90
  • 52 Week High
  • BOC $16.20
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • BOC 49.83
  • ALT 39.67
  • Support Level
  • BOC $13.98
  • ALT $4.33
  • Resistance Level
  • BOC $14.49
  • ALT $4.79
  • Average True Range (ATR)
  • BOC 0.27
  • ALT 0.52
  • MACD
  • BOC 0.04
  • ALT -0.16
  • Stochastic Oscillator
  • BOC 56.64
  • ALT 26.92

About BOC Boston Omaha Corporation

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: